The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial

Publication | Open Access

DOI Full Paper Access

331

Citations

References

2019

Year

Erik J.M. van Bommel, Marcel H.A. Muskiet, Michaël J.B. van Baar, Lennart Tonneijck, Mark M. Smits, Anna L. Emanuel, Andrea Božović, A.H. Jan Danser, Frank Geurts, Ewout J. Hoorn,

Kidney International

Metabolic SyndromeDiabetes ManagementRenal FunctionCardiovascular DiseaseMedicineDiabetesChronic Kidney DiseasePhysiologyType 2Diabetic Kidney DiseaseDiabetes MellitusPharmacologyDouble-blind Red TrialNephrologySglt2 Inhibitor DapagliflozinHealth Sciences